Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Malignancies with Activated Tyrosine Kinases
NCT00171912Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2004
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in hypereosinophilic syndrome (HES), systemic mastocytosis (SM), chronic myelomonocytic leukemia (CMML) and 1 more, sponsored by Novartis. Primary endpoints: Efficacy of imatinib mesylate therapy at 2 years and Safety of imatinib mesylate therapy at 2 years. Started Sep 2004; status: completed.
02
Drugs
03
Conditions
hypereosinophilic syndrome (HES)systemic mastocytosis (SM)chronic myelomonocytic leukemia (CMML)dermatofibrosarcoma protuberans (DFSP)
Beyond the preview
Go deeper on NCT00171912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171912.